Results 41 to 50 of about 7,154 (184)

Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation [PDF]

, 2023
To date, there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected pregnant persons. This target trial emulation study aimed to address this
BJ Cowling (15834218), CKH Wong (16544469), KTK Lau (16544472), Y Daoud (17661372), EHY Lau (16543686), MSH Chung (16544478), KW Cheung (17661369), GM Leung (15834224), ICH Au (16544475)   +8 more
core   +2 more sources

MOLNUPIRAVIR DAN NIRMATRELVIR/RITONAVIR SEBAGAI TERAPI ORAL COVID-19

, 2022
COVID-19 merupakan penyakit infeksi yang disebabkan virus SARS-CoV-2 yang dideklarasikan sebagai pandemik global pada tanggal 11 Maret 2020. COVID-19 dapat berakibat fatal hingga menyebabkan kematian, sehingga diperlukan penanganan yang serius. Obat-obat
Raharjo, Sofyan Budi, Angelina, Emanuela
core   +1 more source

Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort study

International Journal of Infectious Diseases, 2023
Objective: To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction in hospitalization, intensive care unit (ICU) admission, and death ...
Ee Vien Low, Mohan Dass Pathmanathan, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Shahanizan Mohd Zin, Faizah Muhamad Zin, Samha Bashirah Mohamed Amin, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +12 more
doaj   +1 more source

Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study

Scientific Reports, 2023
We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were eligible for nirmatrelvir/ritonavir; 250 who ...
Seth Congdon, Zev Narrowe, Nang Yone, Jacob Gunn, Yuting Deng, Priya Nori, Kelsie Cowman, Marjan Islam, Sharon Rikin, Joanna Starrels   +9 more
doaj   +1 more source

Developmental safety of nirmatrelvir in zebrafish (Danio rerio) embryos

, 2023
Background Nirmatrelvir, in combination with ritonavir, is one of the first orally available antiviral treatment for coronavirus disease 2019 (COVID-19).
Giorgio Tiecco, Eugenia Quiros‐Roldan, Mignani, Luca, Luca Mignani, Sara Ferretti, Zizioli, Daniela, Ferretti, Sara, Tiecco, Giorgio, Zanella, Isabella, Castelli, Francesco, Francesco Castelli, Isabella Zanella, Daniela Zizioli, Quiros-Roldan, Eugenia   +13 more
core   +1 more source

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation studyResearch in context

EClinicalMedicine, 2023
Summary: Background: Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for COVID-19 treatment, but direct comparisons of their effectiveness have been limited.
Eric Yuk Fai Wan, Vincent Ka Chun Yan, Zoey Cho Ting Wong, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Xue Li, Carlos King Ho Wong, Ivan Fan Ngai Hung, Chak Sing Lau, Ian Chi Kei Wong, Esther Wai Yin Chan   +10 more
doaj   +1 more source

Deuteration for Metabolic Stabilization of SARS-CoV‑2 Inhibitors GC373 and Nirmatrelvir

, 2023
Nirmatrelvir and GC373 inhibit the SARS-CoV-2 3CL protease and hinder viral replication in COVID-19. As nirmatrelvir in Paxlovid is oxidized by cytochrome P450 3A4, ritonavir is coadministered to block this.
Béla Reiz (5043116), Bethan L. Donnelly, Bethan L. Donnelly (16715855), Wayne Vuong, Alexia Piercey (16715852), John C. Vederas (174316), M. Joanne Lemieux, James A. Nieman, Tayla J. Van Oers, Wayne Vuong (8103983), Béla Reiz, Karine Auclair, Alexia Piercey, Alexandr Belovodskiy, Tayla J. Van Oers (16715849), James A. Nieman (9524488), M. Joanne Lemieux (11105188), Karine Auclair (1494094), John C. Vederas, Alexandr Belovodskiy (3805996)   +19 more
core   +1 more source

Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections

, 2023
Importance: Ritonavir-boosted nirmatrelvir and molnupiravir are currently used in the US and in other countries to treat nonhospitalized patients who have mild-to-moderate COVID-19 and who are at high risk for progression to severe disease.
Lin, Dan-Yu, Huang, Shuaiqi, Bartley, Patricia, Milinovich, Alex T., Sacha, Gretchen L., Wang, Xiaofeng, Duggal, Abhijit, Fadel, Francois Abi   +7 more
core   +1 more source

Tacrolimus Toxicity in Two Renal Transplant Recipients Treated With Nirmatrelvir/Ritonavir: A Case Series

Annals of Internal Medicine: Clinical Cases, 2023
Since the onset of the SARS-CoV-2 (COVID-19) pandemic, significant effort has been devoted toward developing therapeutics that decrease the morbidity and mortality of COVID-19 infection.
Meaghan Coyne, Myint Aye
doaj   +1 more source

The interaction between nirmatrelvir/ritonavir and sirolimus: a case report of a kidney recipient with renal insufficiency and COVID-19

Journal of International Medical Research
Nirmatrelvir/ritonavir is a novel drug combination authorized by the US Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19).
Yinhua Gong, Dan Shen, Jinfang Shi, Ye Jiang, Jie Gao   +4 more
doaj   +1 more source